Limited Offer
Liquid Biopsy in Urogenital Cancers and its Clinical Utility
- 1st Edition - January 30, 2022
- Editor: Seyed Mohammad Kazem Aghamir
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 8 8 4 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 8 3 9 7 - 6
Liquid Biopsy in Urogenital Cancers and Their Clinical Utility presents updated information on liquid biopsy techniques and their utility for diagnosing urological cancers.… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteLiquid Biopsy in Urogenital Cancers and Their Clinical Utility presents updated information on liquid biopsy techniques and their utility for diagnosing urological cancers. As a promising and recent diagnostic method, these techniques can be used for identifying tumors at initial stage, thus greatly improving treatment outcomes and survivorship. Chapters provide an overview of liquid biopsy as a new tool for diagnosis, monitoring and personalized medicine in urogenital cancers and explain its applicability in different cancer types, including bladder, prostate, kidney and testis tumors, female genital tract and pediatric urogenital tumors.
This is a valuable resource for cancer researchers, oncologists, graduate students, urologists and biomedical researchers who need to understand more about liquid biopsy and its use for urogenital cancers.
- Presents an overview on liquid biopsy techniques and their applications in cancer diagnosis
- Explains how to extract circulating tumor DNA, RNA and circulating tumor cells and extracellular vehicles from blood samples to identify the urology cancers, including testis, prostate, bladder and kidney
- Includes several images and schematic diagrams that illustrate content and facilitate its comprehension
Graduate students, cancer researchers. Medical doctors, oncologists, urologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter 1: Introduction
- Abstract
- Chapter 2: Overview of liquid biopsy
- Abstract
- Acknowledgments
- Introduction
- Circulating tumor cells
- Circulating tumor nucleic acids
- Circulating tumor DNA
- The possible origins of ctDNA and the theory of genometastasis
- Circulating tumor RNA
- Exosomes
- Tumor-educated platelets
- Circulating tumor nucleic acids analysis
- Quantification and characterization of CTCs
- Conclusions
- Chapter 3: Liquid biopsy as a new tool for diagnosis, monitoring, and personalized medicine in urogenital cancers
- Abstract
- Introduction
- Lessons learned from renal cell carcinoma
- Genomic modulation
- Prognostic and predictive biomarkers for urothelial carcinoma of the urinary bladder (UCB)
- Serum biomarkers and circulating tumor cells (CTC)
- Serum biomarkers and circulating RNA in UCB
- Serum biomarker and circulating tumor DNA in UCB
- Liquid biopsies in prostate cancer
- Circulating tumor cells
- Circulating nucleic acids in PC
- Serum tumor markers in germ cell tumors (GCTs)
- Circulating tumor cells in GCTs
- Circulating microRNAs in GCTs
- Circulating DNA in GCTs
- Conclusion
- Chapter 4: Liquid biopsy in bladder tumors
- Abstract
- Introduction
- Precision medicine in bladder cancer
- Advantages and limitations of cell-free DNA in bladder cancer
- cfDNA levels’ measurement in bladder cancer
- Cell-free DNA integrity in bladder cancer
- Cell-free DNA methylation in bladder cancer
- Cell-free DNA mutations in bladder cancer
- ctDNA application in predicting bladder cancer surveillance
- Molecular interrogation of advanced bladder cancer ctDNA analysis
- Next-generation sequencing (NGS) of ctDNA for identifying therapeutic targets
- Using ctDNA for bladder cancer response to therapy
- ctDNA in the context of tumor heterogeneity
- Medical applications of other circulating molecules
- Future perspective
- Conclusion
- Chapter 5: Circulating tumor cells and DNAs in prostate tumors
- Abstract
- Acknowledgment
- Introduction
- ctDNA
- CD44
- PSA−/lo
- Tissue transglutaminase
- RNA
- LncRNAs for diagnosis
- LncRNAs for prediction and prognosis
- Exosomes
- Diagnostic value of exosomal miRNAs
- Prognostic values of exosomal miRNAs
- Tumor-educated platelets
- Tumor-educated macrophage
- Personalized medicine
- Conclusions
- Chapter 6: Liquid biopsy in kidney tumor
- Abstract
- Acknowledgment
- Introduction
- Epidemiology
- Risk factors
- Percutaneous renal mass biopsy
- Detection of circulating tumor cells in renal cell carcinoma
- Epithelial marker-dependent isolation method for CTC detection in renal cancer
- Negative CTC enrichment by hematopoietic cell depletion in renal cancer
- Cell size-based enrichment method
- Circulating protein-coding RNAs and renal cancer
- Circulating noncoding RNAs and renal cancer
- Conclusion
- Chapter 7: Liquid biopsy in male genital tract: Testis tumor
- Abstract
- Acknowledgment
- Introduction
- Circulating tumor DNA and epigenetic factors
- Micro-RNAs
- Circulating tumor cells
- Clinical implications
- Conclusions and future perspectives
- Chapter 8: Liquid biopsy in female genital tract (ovarian cancer, endometrial tumor, and cervical tumor)
- Abstract
- Introduction
- Ovarian cancer
- Cancer-specific mutations
- Chromosomal abnormality
- Aberrant methylation
- Endometrial cancer
- Conclusion
- Chapter 9: Liquid biopsy in pediatric urogenital tumors
- Abstract
- Introduction
- CTC in pediatric urogenital tumors
- Malignant kidney tumors
- Neuroblastoma
- Rhabdomyosarcoma
- Testis tumor
- Current and future aspects
- Conclusions
- Index
- No. of pages: 208
- Language: English
- Edition: 1
- Published: January 30, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780323998840
- eBook ISBN: 9780323983976
SK